Luminomics synthesizes evidence from 300,000+ cancer research papers to deliver real-time, literature-backed clinical decision support at the point of care.
Every feature designed around real clinical workflows — not lab benchmarks.
Semantic search across 300,000+ papers with BGE Cross-Encoder reranking. Ranked by clinical relevance, not keyword match.
KRAS · BRAF · MSI-H · HER2 · NTRK — biomarker-specific evidence retrieval with 6-dimensional case matching.
Real-time guideline cross-referencing. Every recommendation is grounded in Category 1 evidence from leading guidelines.
Automatic interaction screening across oncology regimens. Age-adjusted dose recommendations with renal function considerations.
Live clinicaltrials.gov integration. Matches patients to open trials by mutation, stage, line of therapy, and geography.
Automated trust scoring across 45,000+ papers. Retracted literature flagged. Grade A–C evidence clearly distinguished.
Describe your patient — mutation, stage, line of therapy, comorbidities.
Semantic search + HyDE expansion retrieves the most relevant papers globally.
Cross-Encoder reranking and 5-tier trust scoring filter noise and flag retracted studies.
Receive a NCCN-grounded recommendation with citations, cautions, and open trials.
Luminomics doesn't generate opinions — it retrieves, ranks, and synthesizes published evidence, then presents it in a structured clinical format with full citation trails.
Retracted papers are automatically excluded. Evidence grades are transparent. You always know exactly why a recommendation was made.
Compare FOLFOX, FOLFIRI, immunotherapy, and targeted regimens for any mutation profile with current evidence and trial data.
Age-adjusted recommendations with renal function considerations, frailty scoring, and comorbidity-aware drug interaction alerts.
Instant evidence synthesis for KRAS G12C, BRAF V600E, MSI-H/dMMR, HER2, NTRK fusions, and emerging biomarkers.
Real-time matching to recruiting trials worldwide by mutation, stage, prior therapy, and geographic location.
Instant access to Category 1 recommendations from NCCN and ASCO guidelines, cross-referenced with primary literature.
Automated screening for high-risk interactions — warfarin + fluorouracil, bevacizumab + anticoagulants, and more.
Luminomics is currently in private beta. We are onboarding oncologists and cancer centers for early access.
Request Early Access →